Goldman Sachs initiated coverage of LifeStance with a Neutral rating and $9 price target. As one of the largest pure-play providers of outpatient mental health services in the United States, the company is favorably positioned for several critical trends in the behavioral market, the analyst tells investors. However, the firm's Neutral rating reflects that the most important debate has shifted from demand to conversion of that demand into consistent capacity growth, the analyst added.
